Lung Cancer News and Research

Latest Lung Cancer News and Research

Study shows how ruthenium-based drugs may be more effective at fighting cancer cells

A new study by University of Kentucky researchers shows how light and strained ruthenium-based drugs may be more effective at fighting cancer cells and less toxic to healthy cells than a similar and widely used drug.

12 Jun 2012

VHC extends Obstetrics services to Kaiser Permanente members

Virginia Hospital Center announced today an expansion of services offered at Virginia Hospital Center, to include Obstetrics for Kaiser Permanente's members.

11 Jun 2012

ADAM28 inhibits VWF-mediated cancer cell apoptosis and enhances lung metastases

ADAM28, a metalloproteinase belonging to the ADAM gene family, cleaves the von Willebrand factor (VWF) and inhibits VWF-mediated cancer cell apoptosis, thereby enhancing lung metastases, so inhibiting its expression gives a substantial reduction in lung metastases, according to a study published June 8 in the Journal of The National Cancer Institute.

11 Jun 2012

Piramal to present data on several molecular imaging compounds at SNM annual meeting

Piramal Imaging SA, a subsidiary of Piramal Healthcare Limited, will present data on several compounds from its molecular imaging portfolio at the Society of Nuclear Medicine's 59th annual meeting in Miami Beach, Fla., from June 9 - 13.

10 Jun 2012

High radon levels in Extremadura

Researchers at the University of Extremadura have measured levels of the radioactive gas radon in 130 workplaces in the Spanish region of Extremadura. The results revealed that 13% of shops, schools, offices, museums and other buildings exceeded EU recommended levels. The record for the highest level of radon is held by a cave in the north of Cáceres in Western Spain.

8 Jun 2012

Scientists create cancer model built in the fruit fly Drosophila

Researchers from Mount Sinai School of Medicine developed a cancer model built in the fruit fly Drosophila, then used it to create a whole new approach to the discovery of cancer treatments. The result is an investigational compound AD80 that precisely targets multiple cancer genes.

8 Jun 2012

New data supports clinical role of Cambridge Heart’s MTWA test in managing patients at risk of SCA

Cambridge Heart, Inc., a developer of non-invasive diagnostic tests for cardiac disease, today announced that results of a prospective, 155-patient trial reinforce the value of the Microvolt T-Wave Alternans (MTWA) test as a predictor of life-threatening heart rhythms and Sudden Cardiac Death (SCD).

7 Jun 2012

Artificial noses could allow quick disease screening and ultimately transform diagnostics

Artificial noses have, until now, been used to detect diseases such as urinary tract infection, Helicobacter pylori, tuberculosis, ear, nose and throat conditions and even lung cancer. They have also been clinically tested for use in continuous monitoring of different disease stages.

7 Jun 2012

Debiopharm announces results from Debio 0932 Phase I study on cancer

Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs and companion diagnostics, presented results of a Phase I open-label dose-escalation study with Debio 0932, an oral Heat Shock Protein 90 (HSP90) inhibitor in clinical development as an anti-cancer agent.

7 Jun 2012

High pollution increases risk of repeated heart attacks by over 40%

Air pollution, a serious danger to the environment, is also a major health risk, associated with respiratory infections, lung cancer and heart disease. Now a Tel Aviv University researcher has concluded that not only does air pollution impact cardiac events such as heart attack and stroke, but it also causes repeated episodes over the long term.

6 Jun 2012

Lilly announces final results from ALIMTA Phase III study on NSCLC

Final results from PARAMOUNT, a Phase III study of ALIMTA (pemetrexed for injection) in the continuation maintenance setting, demonstrated improved overall survival in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) treated with ALIMTA continuation maintenance, according to data announced today by Eli Lilly and Company.

5 Jun 2012

New PD-1 blocking antibody shows promise against advanced kidney cancer

An antibody that helps a person's own immune system battle cancer cells shows increasing promise in reducing tumors in patients with advanced kidney cancer, according to researchers at Beth Israel Deaconess Medical Center.

5 Jun 2012

Jennerex announces data from JX-594 clinical studies on cancer

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, today announced that data relating to the company's oncolytic virus therapy for cancer was featured in three separate abstracts during the American Society of Clinical Oncology (ASCO) Annual Meeting currently taking place in Chicago, Illinois.

5 Jun 2012

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

OncoGenex Pharmaceuticals, Inc. announced today data from a Phase 2 study of its investigational compound OGX-427 in chemotherapy-naive metastatic castration resistant prostate cancer (mCRPC) patients will be presented during an oral presentation at the 2012 American Society of Clinical Oncology (ASCO) annual meeting on Tuesday, June 5.

5 Jun 2012

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Oncothyreon Inc. today announced that data from two clinical trials of PX-866, a pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

4 Jun 2012

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

ArQule, Inc. and Daiichi Sankyo Co., Ltd. today announced final results from a randomized, placebo-controlled, double-blind, phase 2 clinical trial with the selective MET inhibitor tivantinib as a single-agent, investigational, second-line treatment in hepatocellular carcinoma (HCC).

4 Jun 2012

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

CytRx Corporation, a biopharmaceutical company specializing in oncology, announces that favorable clinical results from its Phase 1b/2 clinical trial with its tumor-targeting doxorubicin conjugate INNO-206 in patients with advanced solid tumors, primarily soft tissue sarcomas, are being presented today at the American Society of Clinical Oncology (ASCO) conference in Chicago.

4 Jun 2012

Interim results from Bristol-Myers Squibb’s BMS-936558 Phase 1 study on NSCLC, MM and RCC

Bristol-Myers Squibb Company today announced interim results from the expanded Phase 1 dose-ranging study 003 (n=296) of its investigational anti-PD-1 immunotherapy (BMS-936558), which showed clinical activity in patients with previously-treated non small-cell lung cancer (NSCLC), metastatic melanoma and renal cell carcinoma (RCC).

4 Jun 2012

New evidence of important role of next-generation sequencing in cancer treatment

Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced results from two studies using next-generation sequencing (NGS) to provide actionable information about genomic tumor alterations in individual patients' cancers across all solid tumor types.

2 Jun 2012

Study supports wider testing for immune-based therapies to treat advanced non-small cell lung cancer

Two clinical trials led by Johns Hopkins Kimmel Cancer Center researchers in collaboration with other medical centers, testing experimental drugs aimed at restoring the immune system's ability to spot and attack cancer, have shown promising early results in patients with advanced non-small cell lung cancer, melanoma, and kidney cancer.

2 Jun 2012

Lung Cancer News and Research

Latest Lung Cancer News and Research

Study shows how ruthenium-based drugs may be more effective at fighting cancer cells

VHC extends Obstetrics services to Kaiser Permanente members

ADAM28 inhibits VWF-mediated cancer cell apoptosis and enhances lung metastases

Piramal to present data on several molecular imaging compounds at SNM annual meeting

High radon levels in Extremadura

Scientists create cancer model built in the fruit fly Drosophila

New data supports clinical role of Cambridge Heart’s MTWA test in managing patients at risk of SCA

Artificial noses could allow quick disease screening and ultimately transform diagnostics

Debiopharm announces results from Debio 0932 Phase I study on cancer

High pollution increases risk of repeated heart attacks by over 40%

Lilly announces final results from ALIMTA Phase III study on NSCLC

New PD-1 blocking antibody shows promise against advanced kidney cancer

Jennerex announces data from JX-594 clinical studies on cancer

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Final results from ArQule and Daiichi Sankyo’s tivantinib phase 2 trial on HCC

Favorable results from CytRx’s INNO-206 Phase 1b/2 trial on soft tissue sarcomas

Interim results from Bristol-Myers Squibb’s BMS-936558 Phase 1 study on NSCLC, MM and RCC

New evidence of important role of next-generation sequencing in cancer treatment

Study supports wider testing for immune-based therapies to treat advanced non-small cell lung cancer

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in